Mirtazapine Eg (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases norepinephrine release, and by antagonising 5‑HT2 and 5‑HT3 serotonin receptors while stimulating 5‑HT1A receptors. This dual action raises levels of norepinephrine and serotonin in the brain, contributing to its antidepressant effect.

The dosage of Mirtazapine Eg is determined individually by a qualified prescriber based on the patient’s clinical condition, response, and tolerability. Only a healthcare professional can set the appropriate dose and any titration schedule.

Safety of mirtazapine in pregnancy and lactation has not been definitively established. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a healthcare provider.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirtazapine differs from selective serotonin reuptake inhibitors (SSRIs) by its dual noradrenergic and serotonergic activity and its strong antihistaminic effect, which often leads to sedation and weight gain. SSRIs typically have less sedation but may cause gastrointestinal upset; the choice depends on patient‑specific factors and side‑effect profiles.

Mirtazapine Eg should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in humid or excessively hot environments.

Mirtazapine Eg is taken orally, usually once daily in the evening because of its sedative properties. It can be swallowed whole with or without food; however, taking it with a light snack may reduce gastrointestinal discomfort for some patients.

Serious risks include agranulocytosis or severe neutropenia, which can lead to infection, seizures, hepatic dysfunction, hyponatremia, and the emergence or worsening of suicidal thoughts. Patients should be monitored closely for signs of infection, liver problems, electrolyte imbalance, or changes in mood.

Mirtazapine Eg should be avoided in patients with known hypersensitivity to mirtazapine or any of its excipients, those currently taking monoamine oxidase inhibitors (MAOIs), and individuals with severe hepatic impairment unless a specialist advises otherwise. Caution is also advised for patients with a history of bipolar disorder or uncontrolled seizures.